Celldex Therapeutics Inc. (CLDX) Coverage Initiated by Analysts at Brean Capital
Brean Capital assumed coverage on shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) in a research report sent to investors on Tuesday. The firm issued a buy rating and a $16.00 price target on the biopharmaceutical company’s stock.
A number of other research firms also recently weighed in on CLDX. Wedbush reaffirmed a neutral rating and set a $3.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Jefferies Group upped their price target on Celldex Therapeutics to $5.00 and gave the stock a hold rating in a research note on Friday, August 5th. Finally, Cowen and Company reaffirmed an outperform rating and set a $12.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, June 7th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Celldex Therapeutics has a consensus rating of Hold and a consensus price target of $9.75.
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up 2.34% on Tuesday, hitting $4.37. The stock had a trading volume of 654,671 shares. The company’s market capitalization is $439.38 million. The company has a 50-day moving average of $3.75 and a 200 day moving average of $4.16. Celldex Therapeutics has a 52 week low of $2.96 and a 52 week high of $18.62.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02. The company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.96 million. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The firm’s revenue was down 36.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.33) EPS. On average, equities research analysts predict that Celldex Therapeutics will post ($1.34) EPS for the current year.
Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Celldex Therapeutics by 94.9% in the first quarter. JPMorgan Chase & Co. now owns 690,128 shares of the biopharmaceutical company’s stock valued at $2,608,000 after buying an additional 336,049 shares in the last quarter. National Planning Corp increased its stake in Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 1,650 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 33,800 shares in the last quarter. Norges Bank bought a new stake in Celldex Therapeutics during the fourth quarter valued at about $9,378,000. Finally, Bellevue Group AG bought a new stake in Celldex Therapeutics during the first quarter valued at about $605,000. Hedge funds and other institutional investors own 78.41% of the company’s stock.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.